Tag Archives: Jason Mccarthy
Plus Therapeutics (PSTV) Gets a Buy Rating from Maxim Group
Maxim Group analyst Jason McCarthy assigned a Buy rating to Plus Therapeutics (PSTV – Research Report) yesterday and set a price target of $6.00. The company’s shares closed last Friday at $2.10. According to TipRanks.com, McCarthy is a 5-star analyst
Maxim Group Keeps Their Hold Rating on Onconova Therapeutics (ONTX)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Onconova Therapeutics (ONTX – Research Report). The company’s shares closed last Friday at $0.26, close to its 52-week low of $0.10. According to TipRanks.com, McCarthy
Analysts Offer Insights on Healthcare Companies: Biocept (NASDAQ: BIOC) and Biolase (NASDAQ: BIOL)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biocept (BIOC – Research Report) and Biolase (BIOL – Research Report) with bullish sentiments. Biocept (BIOC) In a report released yesterday, Jason
Maxim Group Assigns a Buy Rating on Bellerophon (BLPH)
Maxim Group analyst Jason McCarthy assigned a Buy rating to Bellerophon (BLPH – Research Report) yesterday and set a price target of $22.00. The company’s shares closed last Friday at $8.80. According to TipRanks.com, McCarthy is a 5-star analyst with
Matinas BioPharma (MTNB) Receives a New Rating from Maxim Group
Maxim Group analyst Jason McCarthy initiated coverage with a Buy rating on Matinas BioPharma (MTNB – Research Report) yesterday and set a price target of $3.00. The company’s shares closed last Friday at $0.85. According to TipRanks.com, McCarthy is a
Maxim Group Thinks SCYNEXIS’s Stock is Going to Recover
In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to SCYNEXIS (SCYX – Research Report), with a price target of $15.00. The company’s shares closed last Friday at $4.90, close to its 52-week low of
